Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Francis Mogollon-Duffo


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


F. Mogollon-Duffo1, A. Sultan1, S. Swarup1, N. Jahan1, A.M. Tun2, T. Win Htut3, T.W. Naing4, P.T. Naing5, Y. Mon Myat6, F. Hardwicke1, S. Rehman1, L. Tijani1, N. D'Cunha1, K.Z. Thein1

Author affiliations

  • 1 Hematology Oncology, Texas Tech University, 79430 - Lubbock/US
  • 2 Hematology Oncology, Brooklyn Hospital Center, Brooklyn/US
  • 3 Acute Medicine, Colchester Hospital, CO4 5JL - Colchester/GB
  • 4 Clinical Instructor, Icahn School of Medicine at Mount Sinai, New York City/US
  • 5 Internal Medicine, New York-Presbyterian Hospital Queens, Queens/US
  • 6 Medicine, University College Dublin, Ireland, D04 V1W8 - Dublin/IE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1358


Atezolizumab, an ani-PD-L1 monoclonal antibody, has been used in the treatment of a wide variety of cancers. Recently, atezolizumab has shown significant antitumor activity against non-small cell lung cancer (NSCLC), the majority of lung cancer which is the leading cause of cancer-related mortality in both sexes. The purpose of our study is to consolidate the efficacy of atezolizumab in combination with chemotherapy for first-line treatment of advanced NSCLC.


We systematically conducted a comprehensive literature search using PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019. RCTs utilizing first-line atezolizumab chemoimmunotherapy in patients with advanced NSCLC were incorporated. A generic inverse variance method was used to calculate the estimated pooled hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran’s Q -statistic. Random effects model was applied.


A total of 2725 patients with advanced NSCLC from four phase III RCTs (IMpower – 130, 131, 132 and 150) were eligible. The study arm used standard chemotherapy regimens in combination with atezolizumab while control arm used only standard chemotherapy regimens. The randomization ratio was 2:1 in IMpower130 study and 1:1 in other studies. IMpower131 study included patients with squamous histology and other studies were employed in patients with non-squamous NSCLC. The pooled HR for PFS was statistically significant at 0.64 (95% CI: 0.59-0.70; P < 0.00001) and the pooled HR for OS was 0.83 (95% CI: 0.75- 0.93; P = 0.0008). In non-squamous NSCLC histology group, the pooled HR for PFS was noted at 0.62 (95% CI: 0.56-0.69; P < 0.00001) and the pooled HR for OS was 0.79 (95% CI: 0.70- 0.90; P = 0.0002).


Our meta-analysis demonstrated that first-line atezolizumab in combination with chemotherapy significantly improved PFS and OS compared to standard chemotherapy in patients with advanced NSCLC, regardless of the histology.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.